A phase 1a/1b multicenter, open-label, dose escalation, dose expansion study evaluating the safety, pharmacokinetics and activity of GDC-9545 alone or in combination with palbociclib and/or LHRH agonist in patients with locally advanced or metastatic estrogen receptor-positive breast cancer [GO39932].

  • Richardson, Gary (Primary Chief Investigator (PCI))
  • Baker, Emma (Project Manager)

Project: Research

Project Details

Effective start/end date24/05/1931/12/24


  • Medical Oncology
  • Breast cancer
  • Clinical trial